Abstract
This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Infectious Disorders - Drug Targets
Title: Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Volume: 11 Issue: 1
Author(s): Jo-Anne H. Young
Affiliation:
Keywords: Chronic myelogenous leukemia (CML), chronic granulocytic leukemia (CGL), chronic lymphoid leukemia (CLL), hypogammaglobulinemia, opportunistic infection, Pneumocystis, anti-Pneumocystis prophylaxis, B-cell chronic, white blood cells, alkylating, prednisone, rituximab, alemtuzumab, hairy cell leukemia, neutropenia, monocytopenia, T-cell dysfunction, Sweet's syndrome, chronic myelogenous, myeloid, stem cells, chronic granulocytic leukemia, Allogeneic hematopoietic stem cell, mycobacteria, Aspergillus, legionellosis, salmonellosis, toxoplasmosis, listeriosis, Listeria, Pas-teurella multocida tracheobronchitis, Toxoplasma cyst, Cryptococcus, Chlamydophila psittaci
Abstract: This is a review of the epidemiology and management of infectious complications in contemporary management of chronic leukemias. Patients with chronic leukemias typically are affected by nuisance infections due to the underlying hematologic condition, particularly hypogammaglobulinemia in CLL patients. With active treatment, particularly those agents that cause defects in cell-mediated immunity, the incidence of opportunistic infections increases although endogenous bacterial, mycobacterial, and fungal infections also occur. Exogenous treatment with immunoglobulin and antimicrobial prophylaxis, particularly anti-Pneumocystis prophylaxis, may be indicated in select patients. Routine vaccinations should be maintained in these patients and vaccination early in the course of treatment may result in improve protection.
Export Options
About this article
Cite this article as:
H. Young Jo-Anne, Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias, Infectious Disorders - Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/187152611794407755
DOI https://dx.doi.org/10.2174/187152611794407755 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Vascular Endothelial Dysfunction
Current Drug Targets Nosocomial Infections and Antimicrobial Treatment in Coiled Patients with Aneurysmal Subarachnoid Hemorrhage
Current Drug Targets The Role of Antiplatelet Agents in the Management of Patients Receiving Intracardiac Closure Devices
Current Pharmaceutical Design Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Pathology and Development - Developmental Systems for Target Validation and Drug Screening in Osteoarthritis
Drug Design Reviews - Online (Discontinued) Past and Present Behçet’s Disease Animal Models
Current Drug Targets Long Term Safety and Efficacy of Internal Carotid Artery Adventitial Stripping in Carotid Sinus Syndrome
Current Hypertension Reviews Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets Yielding Criterion of Porcine Thoracic Aorta
Recent Patents on Cardiovascular Drug Discovery Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Feasibility and Efficacy of Low-profile Visual Intraluminal Support Device: A Single Center Five-year Experience
Current Neurovascular Research 3D CT Angiography of Infrarenal Abdominal Aortic Aneurysm with Associated Ectopic Pelvic Kidney: A Case Report of Rare Concomitance
Current Medical Imaging Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Molecular Mechanisms of Restenosis After Percutaneous Peripheral Angioplasty and Approach to Endovascular Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design